The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Clinical Outcomes of Therapeutic Agents That Block the Platelet Glycoprotein IIb/IIIa Integrin in Ischemic Heart Disease
Open accessAbstract
Background —Several platelet glycoprotein (GP) IIb/IIIa receptor antagonists have been evaluated in clinical trials. We conducted a systematic overview (meta-analysis) to assess the effect of these compounds on death, myocardial infarction (MI), and revascularization. Methods and Results —ORs were calculated for 16 randomized, controlled trials of GP IIb/IIIa inhibitors. An empirical Bayesian random-effects model combined the outcomes of 32 135 patients. There was a significant mortality reduction by GP IIb/IIIa inhibitors at 48 to 96 hours, with an OR of 0.70 (95% CI, 0.51 to 0.96; P <0.03), equivalent to a reduction of 1 death per 1000 patients treated. Mortality benefits at 30 days (OR, 0.87; 95% CI, 0.74 to 1.02; P =0.08) and 6 months (OR, 0.97; 95% CI, 0.86 to 1.10; P =0.67) were not statistically significant. For the combined end point of death or MI, there was a highly significant ( P <0.001) benefit for GP IIb/IIIa inhibitors at each time point. The 30-day OR was 0.76 (95% CI, 0.66 to 0.87), or 20 fewer events per 1000 patients treated. For the composite end point of death, MI, or revascularization, there was also a highly significant ( P <0.001) benefit for GP IIb/IIIa inhibitors. At 30 days, the OR was 0.77 (95% CI, 0.68 to 0.86), or 30 fewer events per 1000 patients treated. The risk differences for death, death or MI, and composite outcomes were similar at 6 months, indicating a sustained absolute improvement. Similar benefit was seen when trials were subgrouped by therapeutic indication (percutaneous intervention versus acute coronary syndromes). Conclusions —Application of this new therapeutic class to clinical practice promises substantial benefit for both indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Statistical Methods for Meta-Analysis
Wasserman, S., Hedges, L. V., & Olkin, I. (1988) · Journal of Educational Statistics · doi:10.2307/1164953 · Cited by 10,326
(1994) · New England Journal of Medicine · doi:10.1056/nejm199404073301402 · Cited by 2,589
Quantitative Synthesis in Systematic Reviews
Lau, J., Ioannidis, J. P. A., & Schmid, C. H. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-9-199711010-00008 · Cited by 2,517
(1997) · New England Journal of Medicine · doi:10.1056/nejm199706123362401 · Cited by 1,883
(1998) · New England Journal of Medicine · doi:10.1056/nejm199805213382102 · Cited by 1,321
Discrepancies between Meta-Analyses and Subsequent Large Randomized, Controlled Trials
LeLorier, J., Grégoire, G., Benhaddad, A., Lapierre, J., & Derderian, F. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708213370806 · Cited by 1,171
Systematic Review: Why sources of heterogeneity in meta-analysis should be investigated
Thompson, S. G. (1994) · BMJ · doi:10.1136/bmj.309.6965.1351 · Cited by 1,017
Investigators, T. R. (1997) · Circulation · doi:10.1161/01.cir.96.5.1445 · Cited by 945
Hunt, D. U., Varigos, G., Dienstl, F., Lechleitner, P., DeBacker, G., Kornitzer, M., Cairns, J., Turpie, A. G. G., Fritz-Hansen, P., Skagen, K., et al. (1992) · The Lancet · Cited by 894
Self-citationA Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable Angina
(1998) · New England Journal of Medicine · doi:10.1056/nejm199805213382103 · Cited by 796
Platelet Glycoprotein IIb/IIIa Receptors in Cardiovascular Medicine
Lefkovits, J., Plow, E. F., & Topol, E. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506083322306 · Cited by 754
Self-citationColler, B. S., Peerschke, E. I., Scudder, L. E., & Sullivan, C. A. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110973 · Cited by 746
A note on graphical presentation of estimated odds ratios from several clinical trials
Galbraith, R. F. (1988) · Statistics in Medicine · doi:10.1002/sim.4780070807 · Cited by 663
The´roux, P., Kouz, S., Roy, L., Knudtson, M. L., Diodati, J. G., Marquis, J.-F., Nasmith, J., Fung, A. Y., Boudreault, J.-R., Delage, F., et al. (1996) · Circulation · doi:10.1161/01.cir.94.5.899 · Cited by 180
Schulman, S. P., Goldschmidt‐Clermont, P. J., Topol, E. J., Califf, R. M., Navetta, F. I., Willerson, J. T., CHANDRA, N. C., Guerci, A. D., Ferguson, J. J., Harrington, R. A., et al. (1996) · Circulation · doi:10.1161/01.cir.94.9.2083 · Cited by 108
Self-citationPlatelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease
Lefkovits, J., & Topol, E. J. (1996) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a014698 · Cited by 71
Self-citationFAST PRO : software for meta-analysis by the confidence profile method
Eddy, D. M., & Hasselblad, V. (1992) · Academic Press eBooks · Cited by 68
Self-citationLessons from overviews of cardiovascular trials
Furberg, C. D., & Morgan, T. M. (1987) · Statistics in Medicine · doi:10.1002/sim.4780060316 · Cited by 50
Effects on overviews of early stopping rules for clinical trials
Green, S., Fleming, T. R., & Emerson, S. S. (1987) · Statistics in Medicine · doi:10.1002/sim.4780060329 · Cited by 31
Cited by
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Self-citationMehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S., Natarajan, M. K., Malmberg, K., Rupprecht, H.-J., Zhao, F., Chrolavicius, S., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05701-4 · Cited by 2,809
Cannon, C. P., Weintraub, W. S., Demopoulos, L. A., Vicari, R., Frey, M. J., Lakkis, N., Neumann, F.-J., Robertson, D. H., DeLucca, P. T., DiBattiste, P. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442501 · Cited by 2,103
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181940 · Cited by 1,853
Self-citation
Metadata
- Authors
- Kong, D. F., Califf, R. M., Miller, D. P., Moliterno, D. J., White, H. D., Harrington, R. A., Tcheng, J. E., Lincoff, A. M., Hasselblad, V., & Topol, E. J.
- Venue
- Circulation
- Published
- 1998-12-22
- Volume
- 98
- Issue
- 25
- Pages
- 2829-2835
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1984761420
- Cited by
- 348
- References
- 24
- FWCI
- 35.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.